Member Info for BuenaVista

That isn't peer review. Peer review is independent.

There's still no peer reviewed paper on any aspect, even the preclinical animal work, of Avacta's pre|CISION platform

September/October was the big reveal/promotion of the pipeline/direction. Now we wait whilst BP cogitates.

Do not feed the troll

Do not feed the troll

BD, it was obvious the share price would drift down again without further news, particularly revenue news. It always does.

Enhertu has not been approved for NHS use due to cost (possibly really meaning cost/benefit?) and AstraZeneca and Daiichi's follow on drug, datopotamab deruxtecan, has run into (lack of) efficacy problems so I guess these two would be interested in having Avacta's tech to plug a potential future gap in their oncology portfolio, although they may have other candidates in development with the same or different MoA.

The three indications have been decided but it is unclear what the dosing regimen (dose and frequency) is and whether the first patients have been dosed. The dosing regimen(s) (the same for all three indications?) has/have to be approved by the FDA - and and by the MHRA if the trial is also to include UK sites, which may be a cause of delay if the vibe from the R&D day is to be believed.

Whilst it may be a craze for youths, the numbers are increasing far too quickly for this to be real. If they can hack into businesses and governments, it'd be a piece of pish for Russian bot farms to flood the petition using VPN and fake postcodes.

Was that a guess?

I had a look at the location of signatories on the map and there were black clusters in Moscow and St Petersburg.

Avacta owns 21% of a joint venture company and only had to produce a few Affimers, and you call that a distraction?

All Affimer development work will be prior to the trial starting.

Watch out for LR19128 (LR-19128 PD-L1 XT): https://innovation.lgchem.com/ResearchDevelopment/Pipeline.do XT stands for extended circulatory half-life.

Not much known about it: https://synapse.patsnap.com/drug/56d82287c2cc49f5ab503d776c09ad19#overview

Checkpoint inhibitors in development: https://www.globenewswire.com/news-release/2023/05/10/2665893/0/en/Checkpoint-Inhibitors-Clinical-Trial-Pipeline-Appears-Robust-with-180-Key-Pharma-Players-Actively-Working-in-the-Space-Estimates-DelveInsight.html (Note AVA028 and AVA021 both dropped by Avacta)

Here was the POINT Biopharma pipeline in September 2020: https://web.archive.org/web/20200902102316/http://www.pointbiopharma.com/pipeline

That was before Avacta's licence agreement with POINT Biopharm in January 2021: https://www.biopharminternational.com/view/avacta-enters-license-agreement-with-point-biopharma

I think that must be a misunderstanding by GlobalData.

This is a rundown of POINT's pipeline at the time of acquisition 11 months ago: https://www.pharmamanufacturing.com/industry-news/news/33016880/eli-lilly-completes-point-acquisition

The canSEEK pipeline was all preclinical.

This is the US labelling information for Novartis' LUTATHERA® (lutetium Lu 177 dotatate) injection, which is on the market.

"LUTATHERA is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults"

Lilly may have their own version, but that doesn't seem to make sense.

Newly arrive uber-rampers are so transparent.

He's shameless

Yes, not really a great 'find', ShareCast: https://www.lse.co.uk/news/AVCT/peel-hunt-starts-avacta-at-buy-with-99p-price-target-onarn2svdkvdygt.html

It would help if posters quoted their sauces.

Jeez, she's just an enthusiastic American. It's a different culture. If you're no rah-rah-rah'ing with the best of them and a-whooping and a-hollering with joy at the latest change of management direction, then you're marked out as not part of the team and liable to be 'terminated'. I worked with them. They're a pain.